Sustained stimulation of β 2- and β 3-adrenergic receptors leads to persistent functional pain and neuroinflammation

Brain Behav Immun. 2018 Oct;73:520-532. doi: 10.1016/j.bbi.2018.06.017. Epub 2018 Jun 20.

Abstract

Functional pain syndromes, such as fibromyalgia and temporomandibular disorder, are associated with enhanced catecholamine tone and decreased levels of catechol-O-methyltransferase (COMT; an enzyme that metabolizes catecholamines). Consistent with clinical syndromes, our lab has shown that sustained 14-day delivery of the COMT inhibitor OR486 in rodents results in pain at multiple body sites and pain-related volitional behaviors. The onset of COMT-dependent functional pain is mediated by peripheral β2- and β3-adrenergic receptors (β2- and β3ARs) through the release of the pro-inflammatory cytokines tumor necrosis factor α (TNFα), interleukin-1β (IL-1β), and interleukin-6 (IL-6). Here, we first sought to investigate the role of β2- and β3ARs and downstream mediators in the maintenance of persistent functional pain. We then aimed to characterize the resulting persistent inflammation in neural tissues (neuroinflammation), characterized by activated glial cells and phosphorylation of the mitogen-activated protein kinases (MAPKs) p38 and extracellular signal-regulated kinase (ERK). Separate groups of rats were implanted with subcutaneous osmotic mini-pumps to deliver OR486 (15 mg/kg/day) or vehicle for 14 days. The β2AR antagonist ICI118551 and β3AR antagonist SR59230A were co-administrated subcutaneously with OR486 or vehicle either on day 0 or day 7. The TNFα inhibitor Etanercept, the p38 inhibitor SB203580, or the ERK inhibitor U0126 were delivered intrathecally following OR486 cessation on day 14. Behavioral responses, pro-inflammatory cytokine levels, glial cell activation, and MAPK phosphorylation were measured over the course of 35 days. Our results demonstrate that systemic delivery of OR486 leads to mechanical hypersensitivity that persists for at least 3 weeks after OR486 cessation. Corresponding increases in spinal TNFα, IL-1β, and IL-6 levels, microglia and astrocyte activation, and neuronal p38 and ERK phosphorylation were observed on days 14-35. Persistent functional pain was alleviated by systemic delivery of ICI118551 and SR59230A beginning on day 0, but not day 7, and by spinal delivery of Etanercept or SB203580 beginning on day 14. These results suggest that peripheral β2- and β3ARs drive persistent COMT-dependent functional pain via increased activation of immune cells and production of pro-inflammatory cytokines, which promote neuroinflammation and nociceptor activation. Thus, therapies that resolve neuroinflammation may prove useful in the management of functional pain syndromes.

Keywords: Allodynia; Astrocyte; Beta 2-adrenergic receptor (β(2)AR); Beta 3-adrenergic receptor (β(3)AR); Beta-adrenergic receptor (βAR); Catechol-O-methyltransferase (COMT); Catecholamines; Chronic pain; Epinephrine; Extracellular signal-regulated kinases (ERK); Functional pain; Hyperalgesia; Idiopathic pain; Microglia; Mitogen-activated protein kinase (MAPK); Neuroinflammation; Norepinephrine; Tumor necrosis factor alpha (TNFα); p38.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Catechol O-Methyltransferase / metabolism
  • Catechol O-Methyltransferase Inhibitors / metabolism
  • Catechols / pharmacology
  • Cytokines / metabolism
  • Etanercept / pharmacology
  • Female
  • Fibromyalgia / metabolism
  • Fibromyalgia / physiopathology
  • Hyperalgesia / metabolism
  • Imidazoles / pharmacology
  • Interleukin-1beta / metabolism
  • Interleukin-6 / metabolism
  • Male
  • Microglia / metabolism
  • Mitogen-Activated Protein Kinases
  • Neuroglia / metabolism
  • Pain / metabolism*
  • Pain / physiopathology
  • Phosphorylation
  • Propanolamines / pharmacology
  • Pyridines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, beta / metabolism
  • Receptors, Adrenergic, beta-2 / drug effects*
  • Receptors, Adrenergic, beta-2 / metabolism*
  • Receptors, Adrenergic, beta-2 / physiology
  • Receptors, Adrenergic, beta-3 / drug effects
  • Receptors, Adrenergic, beta-3 / metabolism*
  • Receptors, Adrenergic, beta-3 / physiology
  • Spinal Cord / metabolism
  • Temporomandibular Joint Disorders / metabolism
  • Temporomandibular Joint Disorders / physiopathology
  • Tumor Necrosis Factor-alpha / metabolism
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate
  • Catechol O-Methyltransferase Inhibitors
  • Catechols
  • Cytokines
  • Imidazoles
  • Interleukin-1beta
  • Interleukin-6
  • Propanolamines
  • Pyridines
  • Receptors, Adrenergic, beta
  • Receptors, Adrenergic, beta-2
  • Receptors, Adrenergic, beta-3
  • Tumor Necrosis Factor-alpha
  • Catechol O-Methyltransferase
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • Etanercept
  • SB 203580
  • OR486